Clinical and Research Advances in Dementia Prevention: Biomarkers and Early Signs
DOI:
https://doi.org/10.35830/mcya.vi25.568Keywords:
Cognitive impairment, biomarkers, timely detectionAbstract
Cognitive disorders, such as Alzheimer’s Disease, are among the leading causes of morbidity in the adult population. Furthermore, their incidence increases with aging. The growth of the older adult population drives the search for effective methods for the timely detection of susceptibility to develop dementia. The search for a differential diagnosis in preclinical stages requires techniques that encompass physiological, morphological, and behavioral parameters, as current diagnoses are initially made through clinical criteria. In Mexico, observation is the primary technique used as the first approach to the condition. We conducted a systematic review of various techniques, such as biomarkers, clinical aspects (early signs and symptoms of cognitive decline) and predisposition to develop dementia, proposing alternatives such as the analysis of electroencephalographic activity and the assessment of visuospatial memory quality
Downloads
References
Altuna-Azkargorta, M., & Mendioroz-Iriarte, M. (2018). Biomarcadores sanguíneos en la enfermedad de Alzheimer. Neurología. https://doi.org/10.1016/j.nrl.2018.03.006
Balusu, S., Horré, K., Thrupp, N., Craessaerts, K., Snellinx, A., Serneels, L., T’Syen, D., Chrysidou, I., Arranz, A. M., Sierksma, A., Simrén, J., Karikari, T. K., Zetterberg, H., Chen, W. T., Thal, D. R., Salta, E., Fiers, M., & De Strooper, B. (2023). MEG3 activates necroptosis in human neuron xenografts modeling Alzheimer’s disease. Science
Bonilla-Santos, Jasmín, Zea-Romero, Erika Yisseth, Cala-Martínez, Dorian Yisela, & González-Hernández, Alfredis. (2021). Marcadores Cognitivos, Biológicos, Anatómicos Y Conductuales Del Deterioro Cognitivo Leve Y La Enfermedad De Alzheimer. Una Revisión Sistemática. Revista Ecuatoriana de Neurología, 30(2), 57-67. https://doi.org/10.46997/revecuatneurol30200057
Carrillo-Mora, Paul. (2010). Sistemas de memoria: reseña histórica, clasificación y conceptos actuales. Primera parte: Historia, taxonomía de la memoria, sistemas de memoria de largo plazo: la memoria semántica. Salud mental, 33(1), 85-93. http://www.scielo.org.mx/scielo.php?script=sci_arttext&pid=S0185-33252010000100010&lng=es&tlng=es
Cope, Z. A., Murai, T., & Sukoff Rizzo, S. J. (2022). Emerging Electroencephalographic Biomarkers to Improve Preclinical to Clinical Translation in Alzheimer’s Disease. Frontiers in Aging Neuroscience, 14. https://doi.org/10.3389/fnagi.2022.805063
Farzadfar, F., Naghavi, M., Sepanlou, S. G., Moghaddam, S. S., Dangel, W. J., Weaver, N. D., ... & Mahdavi, M. M. (2022). Health system performance in Iran: a systematic analysis for the Global Burden of Disease Study 2019. The Lancet, 399(10335), 1625-1645.
Gutiérrez Robledo, L. M., García Peña, M.C, Roa Rojas, P.A, Martínez Ruiz, A.(2017). La Enfermedad de Alzheimer y otras demencias como problema nacional de salud. Academia Nacional de Medicina de México (ANMM). ISBN 978-607-443-721-8
Grande, G., Qiu, Ch. y Fratiglioni, L. (2020). Prevention of dementia in an ageing world: Evidence and biological rationale. Ageing Research Reviews 64; 101045, 1568-1637
Graff-Radford, J., Yong, K. X. X., Apostolova, L. G., Bouwman, F. H., Carrillo, M., Dickerson, B. C., Rabinovici, G. D., Schott, J. M., Jones, D. T., & Murray, M. E. (2021). New insights into atypical Alzheimer’s disease in the era of biomarkers. The Lancet Neurology, 20(3), 222–234. https://doi.org/10.1016/s1474-4422(20)30440-3
López-Vázquez, M. A., Varela-Montes, J., Serrano-Corral, M. L., Junco-Muñoz, M. L., & Olvera-Cortés, M. E. (2024). Interacción del tratamiento y el control de la presión en el deterioro de la memoria incidental visuoespacial en pacientes con hipertensión arterial sistémica. Archivos de cardiología de México, 94(1), 25-32.
Hajar Ahmadieh, & Ghassemi, F. (2022). Assessing the Effects of Alzheimer Disease on EEG Signals Using the Entropy Measure: A Meta-analysis. Basic and Clinical Neuroscience, 13(2), 153–164. https://doi.org/10.32598/bcn.2021.1144.3
Instituto Nacional de Estadística y Geografía (INEGI). (2023). Encuesta Nacional sobre Salud y Envejecimiento en México (ENASEM) 2021. https://www.inegi.org.mx
Lakhan, S. (2019, May 9). Alzheimer Disease: Practice Essentials, Background, Anatomy. Medscape.com. https://emedicine.medscape.com/article/1134817-overview
Livingston, G., Huntley, J., Sommerlad, A., Ames, D., Ballard, C., Banerjee, S., Brayne, C., Burns, A., Cohen-Mansfield, J., Cooper, C., Costafreda, S. G., Dias, A., Fox, N., Gitlin, L. N., Howard, R., Kales, H. C., Kivimäki, M., Larson, E. B., Ogunniyi, A., Orgeta, V., … Mukadam, N. (2020). Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet (London, England), 396 (10248), 413-446. https://doi.org/10.1016/S0140-6736(20)30367-6
Simrén, J., Elmgren, A., Blennow, K., & Zetterberg, H. (2023). Fluid biomarkers in Alzheimer’s disease. Advances in Clinical Chemistry, 112, 249–281. https://doi.org/10.1016/bs.acc.2022.09.006
Scheltens, P. (2021). Alzheimer’s disease. The Lancet, 397(10284), 1577–1590. https://doi.org/10.1016/S0140-6736(20)32205-4
Teunissen, C. E., Verberk, I. M. W., Thijssen, E. H., Vermunt, L., Hansson, O., Zetterberg, H., van der Flier, W. M., Mielke, M. M., & Del Campo, M. (2022). Blood-based biomarkers for Alzheimer’s disease: towards clinical implementation. The Lancet. Neurology, 21(1), 66–77. https://doi.org/10.1016/S1474-4422(21)00361-6
Pardi, P.C, Santos, G.A.A, Silva Gois, J.C, Braz Jr, R.G, & Olave, E. (2017). Biomarkers and Image Markers of Alzheimer's Disease. International Journal of Morphology, 35(3), 864-869. https://dx.doi.org/10.4067/S0717-95022017000300011
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Milenaria, Ciencia y arte
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
